Methyl mercury pharmacokinetics in man: a reevaluation

Area of Science:

• Environmental Health
• Toxicology
• Pharmacokinetics

Background:

• Methylmercury exposure poses significant health risks.
• Understanding methylmercury pharmacokinetics is crucial for risk assessment.
• Previous models did not fully explain mercury excretion patterns.

Purpose of the Study:

• To analyze methylmercury pharmacokinetics using two distinct models.
• To compare the predictive accuracy of models considering only methylmercury versus methylmercury and inorganic mercury.
• To determine methylmercury half-life in humans.

Main Methods:

• Analysis of existing data from Aberg et al. and Miettinen et al.
• Development and application of two pharmacokinetic models (Model I and Model II).
• Simulation of mercury excretion (fecal and urinary) and body burden over time.

Main Results:

• Model I failed to explain continuous urinary mercury increase.
• Model II accurately simulated both fecal and urinary mercury excretion.
• Model II predicted methylmercury half-lives of 51 and 56 days, consistent with other studies.

Conclusions:

• Model II, incorporating inorganic mercury, provides a more precise description of methylmercury pharmacokinetics.
• The model accurately accounts for mercury excretion and declining blood mercury proportions.
• Estimated methylmercury half-lives are comparable to previously reported values.